Indaptus Therapeutics is trading 5.46% down at $1.12 based on the provided live price context; searches found no confirmed company-specific announcement on August 12, 2026 explaining the decline.
- The next quarterly report is estimated for August 12–14, not confirmed, and should not be treated as the catalyst.
- Broader U.S. markets are modestly higher, offering no clear market-wide explanation for the isolated drop.